A new therapy for the most aggressive type of brain cancer can extend patients' survival while cutting the length of ...

MimiVax, Inc. and UI Pharmaceuticals are proud to announce the successful clinical manufacture of SurVaxM, a novel immunotherapeutic vaccine targeting Glioblastoma (GBM), at ...

Diakonos Oncology, a clinical-stage biotechnology company leveraging proprietary dendritic cell technology to address critical and unmet therapeutic needs in late-stage and aggressive cancers, ...

The newly approved methastatic Renal Cell Cancer (mRCC) Phase 1/2a trial began in 4Q24, and Genenta expects to treat six ...

Kindeva Drug Delivery, a global CDMO and drug delivery expert, and Emervax, a developer of a proprietary circular RNA-based vaccine platform (emxRNATM), today announced an exclusive partnership to ...

CVGBM, an investigational cancer vaccine, induced T-cell responses in patients with MGMT-unmethylated glioblastoma.

CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock ...

Russia claims a breakthrough in cancer treatment with a personalized mRNA vaccine, designed to train the immune system to ...

RS, AJ, TS, SB, MUB, KM, HM, ACM, GBM, AM, TM, PM, SR, SS ... Competing interests HM is an investigator on sponsored vaccine trials. Her institution receives funding from Pfizer and GSK for ...

ERC-1671 is under clinical development by ERC Belgium and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM).

SurVaxM is under clinical development by MimiVax and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM).

1Department of Pathology and Krantz Family Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 2Broad Institute of Harvard and MIT, Cambridge, ...